Answers are grounded in this paper and cite their sources.
Background Pleural fluid cytology represents a minimally invasive diagnostic method in patients with suspected malignant pleural effusion. It is often taught that triplicate sampling should be obtained in suspected malignancy to maximize sensitivity, although a paucity of supporting data exists. We sought to determine whether triplicate pleural fluid sampling increases the sensitivity for malignancy at our institution. Methods Patients for whom ≥3 consecutive pleural fluid cytology specimens were submitted between January 2010 and June 2018 (N = 124) were identified in our laboratory information system. Data were retrieved from the cytology report. For patients with a subsequent pleural biopsy specimen, the final diagnosis was obtained from the pathology report. Data were analyzed using descriptive statistics. Results "Positive for malignant cells" was diagnosed in 9.7% of initial specimens, in 13.7% with 2 specimens, and in 15.3% with 3 specimens. Sensitivity increased from 37.9% to 55.2% with triplicate sampling. Negative predictive value increased from 65.4% to 72.3%. Repeat sampling yielded a change in diagnosis in 32.3% of patients, whereas only 5.6% were clinically significant. More than half of patients (57.3%) remained negative over all samples. Conclusions Repeat sampling resulted in the detection of additional malignancies, with an increase in sensitivity and negative predictive value. The yield of new malignant diagnoses is reduced with each successive specimen. When there is a high suspicion of malignancy, repeat pleural fluid specimens must be weighed against more invasive methods that offer increased sensitivity (eg, pleuroscopy with pleural biopsy).
No takes yet. Share an insight, caveat, or question.
DeCoste et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: